Research Conducted and Supported by the National Institutes of Health (NIH) in Addressing Zika Virus Disease

Testimony before the
House Committee on Energy and Commerce
Subcommittee on Oversight and Investigations

Anthony S. Fauci, M.D.

Director

National Institute of Allergy and Infectious Diseases
National Institutes of Health

March 2, 2016
Mr. Chairman, Ranking Member DeGette, and Members of the Subcommittee:

Thank you for the opportunity to discuss the National Institutes of Health (NIH) research response to Zika virus, an emerging public health threat of international concern. I direct the National Institute of Allergy and Infectious Diseases (NIAID), the lead NIH institute for conducting and supporting research on emerging and re-emerging infectious diseases, including those caused by flaviviruses such as Zika virus.

The Administration is taking appropriate action to protect the American people and, as you know, it announced a request to Congress for approximately $1.9 billion in emergency funding to enhance ongoing efforts to prepare for and respond to outbreaks of the Zika virus, both domestically and internationally. This includes funding for work on the development of vaccines and diagnostics and to improve scientific understanding of the disease.

The overarching mission of NIAID is to conduct and support research to better understand, treat, and prevent infectious and immunologic diseases. This is accomplished through a spectrum of research, from basic studies of the mechanisms of disease to applied research focused on developing interventions such as diagnostics, therapeutics, and vaccines. As part of this mission, NIAID has a dual mandate encompassing both research on ongoing public health issues and the capability to respond rapidly to newly emerging and re-emerging infections such as Zika virus.

These emerging and re-emerging disease threats, whether man-made or naturally occurring, are perpetual challenges, in part due to the capacity of microbial pathogens to evolve rapidly and adapt to new ecological niches. To address the challenges posed by emerging infectious diseases, NIAID employs both targeted, disease-specific research as well as broad-spectrum approaches. NIAID maximizes its efforts by prioritizing the development of drugs
effective against multiple bacteria or viruses, and “platform” technologies to facilitate rapid
development of vaccines and diagnostics applicable to multiple infections.

NIAID is well-positioned to rapidly respond to infectious disease threats as they emerge
by leveraging fundamental, basic research efforts; domestic and international research
infrastructure that can be quickly mobilized; and productive partnerships with industry. NIAID
provides preclinical research resources to scientists in academia and private industry worldwide
to advance translational research against emerging and re-emerging infectious diseases. These
resources are designed to bridge gaps in the product development pipeline and lower the
scientific, technical, and financial risks incurred by industry in order to incentivize them to
partner with us in the advanced development of effective countermeasures. NIAID also supports
our Vaccine and Treatment Evaluation Units (VTEUs), a research network that conducts clinical
trials to quickly investigate promising therapeutic and vaccine candidates when public health
needs arise. NIAID collaborations with other federal agencies, including those undertaken within
the Department of Health and Human Services (HHS) Public Health Emergency Medical
Countermeasures Enterprise (PHEMCE), help advance progress against newly emerging public
health threats. In addition, partnerships with academia, the biotechnology and pharmaceutical
industries, and international researchers and organizations such as the World Health
Organization (WHO) and WHO’s regional office, the Pan American Health Organization
(PAHO), are integral to these efforts.

OVERVIEW OF ZIKA VIRUS

Zika virus is a flavivirus. These viruses typically are transmitted by mosquitoes and often
have the ability to spread quickly to new geographic locations because of the widespread
prevalence of these vectors. Other well-known flaviviruses include dengue virus and yellow fever virus; like Zika virus they are transmitted by Aedes mosquitoes. Zika virus was discovered in monkeys in Uganda in 1947 and is now endemic to Africa and Southeast Asia. During the past decade it has emerged in other areas of the world, including Oceania, the Caribbean, and Central and South America, where countries, notably Brazil, are currently experiencing unprecedented Zika transmission.

Infections caused by Zika virus are usually asymptomatic. About 20 percent of infected individuals experience clinical symptoms such as fever, rash, joint pain, and conjunctivitis (red eyes). Symptoms of Zika virus infection in humans are typically mild and brief, with very low hospitalization and fatality rates. The recent outbreak of Zika virus disease in Brazil has coincided with a reported increase in the number of infants born with microcephaly, a birth defect characterized by an abnormally small head resulting from an underdeveloped and/or damaged brain. In addition, increases in suspected cases of Guillain-Barré syndrome (GBS), a rare, acute, immune-mediated peripheral nerve disease that leads to weakness, sometimes paralysis, and infrequently, respiratory failure and death, have been noted in Brazil and other countries in the Americas.

Further research is needed to better understand the effect of Zika virus infection on the body, particularly during pregnancy; to investigate the potential relationship between Zika infection and congenital abnormalities including microcephaly, as well as to explore the potential relationship between Zika infection and GBS; and to develop better diagnostics, vaccines and treatments, and new methods of vector control. Currently, no vaccines or specific therapeutics are available to prevent or treat Zika virus disease. Improved diagnostic tests also are needed because Zika virus infection causes non-specific symptoms or no symptoms at all and can be
difficult to distinguish by antibody screening tests from other mosquito-borne infections such as dengue, malaria, and chikungunya. Moreover, current antibody screening tests can be falsely positive or inconclusive if the individual was previously infected with related viruses such as dengue, which is prevalent in South America and the Caribbean. Therefore, a positive result with the antibody screening test requires an additional test to confirm the diagnosis.

**NIH RESEARCH ON ZIKA VIRUS**

NIAID has a longstanding commitment to flavivirus research, including extensive efforts to combat diseases such as dengue, West Nile virus, and yellow fever. This research has informed our understanding of the viral genetics, vector biology, and pathogenesis of flaviviruses and provides a strong foundation for our efforts to learn more about Zika virus. NIAID has responded to the newly emerging Zika virus disease outbreak by expanding our portfolio of basic research on Zika virus and other flaviviruses. NIAID also is accelerating efforts to develop improved diagnostics and candidate therapies for Zika virus as well as prioritizing the development of Zika virus vaccines. In addition, screening tests and pathogen reduction technologies are critically important to assure safety of the U.S. blood supply.

The emergency funding for NIH would support development of vaccines to prevent Zika virus infection, from the discovery phase through preclinical and eventually clinical testing. In addition, the funds would support basic research to understand the natural history, viral biology and pathogenesis, including potential links to microcephaly; establishment of animal models to test candidate countermeasures; development of rapid, sensitive, and specific diagnostic tests; and discovery and preclinical development of new therapeutics to treat disease caused by Zika virus. This research is necessary to better understand this emerging infection and uncover the best ways to diagnose, treat, and prevent Zika virus disease.
In January 2016, NIAID issued a notice to researchers highlighting NIH's interest in supporting research and product development to combat Zika virus. Areas of high priority include basic research to understand viral replication, pathogenesis, and transmission, as well as the biology of the mosquito vectors; potential interactions with co-infections such as dengue and yellow fever viruses; animal models of Zika virus infection; and novel vector control methods. In addition, NIH is soliciting Zika virus research to develop sensitive, specific, and rapid clinical diagnostic tests; drugs against Zika virus as well as broad spectrum therapeutics against multiple flaviviruses; and effective vaccines and vaccination strategies.

NIAID also is partnering with other NIH institutes, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Dental and Craniofacial Research, to accelerate Zika virus research as it relates to the mother-infant pair. The Institutes issued a notice that indicates NIH’s interest in supporting research to understand transmission, optimal screening and management in pregnancy, and the mechanisms by which Zika virus affects the developing nervous system, including potential links to microcephaly and other congenital abnormalities.

**DEVELOPING TOOLS TO COMBAT ZIKA VIRUS**

In response to public health concerns about Zika virus, NIAID has accelerated ongoing flavivirus research efforts to speed the development of tools that could help control current and future outbreaks of Zika virus.
**Vector Control**

For many years, NIAID has supported extensive research to understand the biology of mosquitoes to help develop tools to limit the spread of deadly mosquito-borne diseases such as dengue and malaria. This research aids in vector control strategies to reduce mosquito bites or limit mosquito populations. In the Americas, Zika virus is transmitted primarily by *Aedes aegypti* mosquitoes, and vector control or other methods to prevent exposure to these mosquitoes are currently the only ways to prevent Zika infection. NIAID plans to support vector competence studies to test various mosquito species for their ability to carry and transmit Zika virus and for insecticide resistance. Understanding the specific mosquito species involved in Zika outbreaks and which insecticides may be effective against them will aid current vector control efforts and may inform novel mosquito control strategies in the future.

**Diagnostics**

Accurate diagnostic tests for Zika virus infection are needed to distinguish it from other flavivirus infections and to identify women who have been infected with Zika virus during pregnancy and may be at risk for developing fetal complications. Blood, organ, and tissue donor screening tests are also needed to assure the safety of transfusion and transplantation in areas of active mosquito-borne virus transmission. Currently, Zika virus itself can often be detected during the acute phase of infection and up to seven days after the onset of symptoms using diagnostic tests for viral RNA (RT-PCR test). While prior infection can be detected by testing for the presence of antibodies against Zika virus, assays for Zika antibodies may also detect or cross-react with antibodies against other flaviviruses, particularly dengue virus. For this reason, a positive antibody test does not definitively confirm prior Zika virus infection in the setting of possible co-infection or prior infection with dengue and other related viruses, and separate
confirmatory testing is required. This is a particular concern in South America where there is a high level of exposure to other flaviviruses, particularly dengue virus.

To facilitate the development of improved Zika virus diagnostic tests, NIAID grantees are working to generate antibodies that can distinguish between Zika virus and dengue virus. They also are working to identify biosignatures unique to Zika infection that could form the basis of additional rapid, specific, and sensitive diagnostic tests. In addition, NIAID is pursuing the development of a mouse model of Zika virus infection that could be used to test new diagnostic and therapeutic tools.

**Vaccines**

A safe and effective Zika vaccine would be a very valuable tool to help stop the spread of infection and prevent future outbreaks. NIAID is investigating multiple Zika virus vaccine candidates, including vaccines based on technologies that have shown promise in targeting other flaviviruses. The NIAID Vaccine Research Center (VRC) is pursuing a DNA-based vaccine for Zika virus that is similar to a West Nile virus vaccine previously developed by NIAID. The West Nile vaccine candidate was shown in Phase 1 testing to be safe and generated a strong immune response in humans, offering a model for Zika vaccine development. NIAID scientists also are designing a live, attenuated vaccine, using an approach similar to that used for making a vaccine against the closely related dengue virus. The dengue vaccine candidate showed an excellent safety profile and generated strong immune responses in early-phase clinical trials. In January, a large Phase 3 trial assessing the dengue vaccine candidate was launched in Brazil in collaboration with the Butantan Institute. In addition, NIAID grantees are in the early stages of developing a Zika virus vaccine based on a recombinant vesicular stomatitis virus – the same
animal virus used successfully to create an investigational Ebola vaccine. Plans are underway to evaluate this potential vaccine construct in tissue culture and animal models.

While these approaches are promising, it is important to realize that the development of investigational vaccines and the clinical testing to establish whether they are safe and effective takes time. Although a safe and effective, fully licensed Zika vaccine will likely not be available for a few years, we plan to begin early-stage clinical testing of one or more NIAID-supported vaccine candidates in 2016.

**Therapeutics**

NIAID has an active program to screen for antiviral drugs active against viruses in the flavivirus family, including dengue, West Nile, yellow fever, and Japanese encephalitis viruses, as well as the closely related hepatitis C virus. NIAID has enhanced these efforts with the recent development of an assay to test compounds for antiviral activity against Zika virus. NIAID will make this test available to the research community and will soon test 10 antiviral compounds with activity against other flaviviruses to determine if they are effective against Zika virus. Promising drug candidates identified by the assay could be further tested in a small animal model of Zika virus infection developed with NIAID support. The ultimate goal of NIAID-supported flavivirus therapeutic research is to develop a broad-spectrum antiviral drug that could be used against a variety of flaviviruses, including Zika.

**Emergency Request for Vaccine Research and Diagnostic Development and Procurement**

As I noted in the introduction to my testimony, the Administration has announced an emergency funding request of approximately $1.9 billion to combat the Zika virus both domestically and internationally. Included in the request are resources for Zika-related vaccine research, rapid advanced development, and commercialization of new vaccines and diagnostic
tests for Zika virus. The funding will allow NIH to build upon existing resources and work to develop a vaccine for Zika virus and the chikungunya virus, which is spread by the same type of mosquito. Funding will accelerate this work and improve scientific understanding of the disease to inform the development of additional tools to combat it. The request also includes resources for FDA to support Zika virus medical product development, including the next-generation diagnostic devices. We look forward to working with the Congress to implement this request.

COLLABORATIONS

Investigation of emerging and re-emerging infectious diseases requires expertise from a variety of fields. In the case of Zika virus, studies of virology, immunology, natural history, neurology, and neonatology will be required to fully understand the pathogenesis of this infection. As mentioned previously, NIAID is partnering with other NIH institutes including NICHD and NINDS to better understand the potential association between Zika virus infection and neonatal defects, particularly microcephaly.

NIAID also is employing partnerships with research institutions in South America to advance research on Zika virus infection; additional collaborations with academic, industry, and government partners are under active exploration. NIAID held a joint meeting in December 2015 with Brazilian research institute Fiocruz in which Zika was a key area of concentration. In addition, NIAID is collaborating with other HHS agencies in responding to the Zika epidemic. For example, NIAID, CDC, BARDA, ASPR, and FDA are jointly convening a Zika virus workshop on March 28-29, 2016, where the latest information on Zika virus will be discussed by experts from Federal Agencies, academia, and pharmaceutical and biotechnology
companies. Topics to be addressed at the workshop include virology, epidemiology, possible links to microcephaly, and efforts to develop diagnostics, therapeutics, and vaccines.

**CONCLUSION**

NIH is committed to continued collaboration with HHS agencies and other partners across the U.S. government in advancing research to address Zika virus infection, and we look forward to working with the Congress to implement the President’s emergency funding request. As part of its mission to respond rapidly to emerging and re-emerging infectious diseases throughout the world, NIAID is expanding our efforts to elucidate the biology of Zika virus and employ this knowledge to develop needed tools to diagnose, treat, and prevent disease caused by this virus. In particular, NIAID will pursue the development of safe, effective vaccines to prevent disease caused by Zika and chikungunya viruses.